Eptinezumab, is sold under the brand name Vyepti.
A medication used for the preventive treatment of migraine in adults.
It is a humanized monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.
It is administered by intravenous infusion.
A Calcitonin gene-related peptide antagonist.
The benefit of eptinezumab in comparison to placebo was assessed based on the change in the number of migraine days per month during the first three-month treatment period.
It is administered by intravenous infusion.
Drug class-Calcitonin gene-related peptide antagonist.
The benefit and side effects of eptinezumab were evaluated in two clinical trials of adult subjects 18 – 71 years of age with a history of migraine headaches.
Trial 1 enrolled subjects with a history of episodic migraine headaches and Trial 2 enrolled subjects with chronic migraine headaches.
Subjects were assigned to receive one of two doses of eptinezumab or placebo injections every three months for a total of twelve months in Trial 1, and for a total of 6 months in Trial 2.